

TETRATHERIX EXPORTS FIRST TETRAMATRIX™ POLYMER TO THE US

31 August 2026

Precision Medicine Franchise

Highlights

- **First commercial shipment of Tetramatrix™ polymer** exported to the United States under the STEPP product development program.
- Shipment of validation material marks the **first revenue-generating supply of product under Tetratherix's Precision Medicine franchise**, launched in March 2026.
- Product revenue is in addition to the existing US\$3M annual exclusive licence fee.
- Shipment follows the **FDA assigning a UNII for our Tetramatrix™ platform polymer** (branded as STEPP), successfully obtained in June.
- Commercial milestone coincides with **another scientific validation of our technology**: peer-reviewed publication of the underlying STEPP science accepted in the International Journal of Pharmaceutics, providing **independent validation of the Tetramatrix™ polymer as an intranasal delivery platform for GLP-1 peptides**.
- **Manufacturing and quality systems have now successfully scaled from pilot to commercial-grade production** to support the export of the polymer within our current manufacturing facility. We have now paved the path for the Tetramatrix™ polymer production to scale significantly upon the commissioning of our new TTX advanced manufacturing campus.

First Commercial Shipment

Tetratherix Limited (ASX:TTX) (**Tetratherix**) is pleased to announce that it has despatched its first commercial shipment of Tetramatrix™ polymer to the United States, marking the beginning of product revenue generation for Tetratherix's Precision Medicine franchise.

The shipment is being exported to our US partner under the exclusive licence and supply agreement announced in March 2026. Superpower Health, Inc. is collaborating to develop STEPP-based intranasal delivery products for the US consumer and longevity market. This first shipment will enable a targeted and deliberate trial period to finalise the operational supply process and, more importantly, begin data collection.

The shipment follows successful completion of Tetratherix's export clearance pathway for the underlying Tetramatrix™ polymer technology, and the scale-up of the manufacturing and quality systems from pilot to commercial-grade production.

The US FDA assigned a unique identifier number (**UNII**) for our Tetramatrix™ platform polymer (branded as STEPP), successfully obtained in June. Importantly, this formalises our Tetramatrix™ proprietary polymer substance registration and enables the export pathway to the US market for our Precision Medicine franchise.

This first shipment follows over five years of collaborative research and development in drug delivery across mRNA, proteins, peptides and small molecules across multiple research partners including global pharmaceutical leaders and world leading researchers. This further builds on Tetratherix's broader strategy of using its single core Tetramatrix™ polymer chemistry to support multiple medical product derivatives across both regenerative medicine and precision medicine.

31 August 2026

Precision Medicine Franchise

Will Knox, CEO:

"This first commercial dispatch of our proprietary polymer is a significant proof point for Tetratherix – it demonstrates that we can take Tetramatrix™ from validated science through to commercial-grade product in the hands of a US partner. It marks the transition of our Precision Medicine franchise from a licensing agreement on paper into a genuine, revenue-generating supply relationship, and reinforces the scalability of our platform across multiple product derivatives."

Anchored By Science – Peer Reviewed Publication

Separately, Tetratherix is pleased to advise that a peer-reviewed manuscript detailing the science underpinning the STEPP program has been accepted for publication in the International Journal of Pharmaceutics.

The paper is titled "Intranasal delivery of Semaglutide using a thermoresponsive PNPFO nanocarrier: Formulation development, characterization and biological evaluation" and was co-authored with collaborators from **Macquarie University, the Woolcock Institute of Medical Research and Aptar Pharma, Inc.**

The study demonstrates that Tetratherix's PNPFO polymer can be formulated as a nanocarrier for intranasal delivery of semaglutide, a GLP-1 receptor agonist, **achieving enhanced transport across nasal epithelial tissue and prolonged nasal retention in preclinical models.** The publication provides independent, peer-reviewed validation of the same core Tetramatrix™ polymer chemistry now being exported to the United States, and further supports the precision medicine strategy in peptide delivery.

Investor Hub

The Tetratherix Investor Hub platform provides existing and prospective shareholders with real-time access to ASX announcements, reports and presentations. You can visit the Tetratherix Investor Hub at:



Authorised for release by the CEO.

For further information contact:

Jacob Pfeffer
General Counsel | Chief of Staff | Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com